The genetic evaluation of dilated cardiomyopathy (DCM) has been challenging, owing in large part to marked genetic heterogeneity. However, lower costs from next-generation sequencing have enabled gene discovery and the expansion of genetic testing panels. These advances have improved molecular diagnostics and predictive testing in DCM. We provide a rationale and recommendation for clinical genetic testing in all DCM cases.
Morales, A., & Hershberger, R. E. (2015). The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy. Canadian Journal of Cardiology, 31(11), 1309–1312. https://doi.org/10.1016/j.cjca.2015.06.034